Circulating microRNA signature in non-alcoholic fatty liver disease: From serum non-coding RNAs to liver histology and disease pathogenesis

Gut

Volumn 64, Issue 5, 2015, Pages 800-812

  Pirola, Carlos J ^a   Gianotti, Tomas Fernández ^a   Castaño, Gustavo O ^b   Mallardi, Pablo ^c   Martino, Julio San ^c   Ledesma, María Mora Gonzalez Lopez ^d   Flichman, Diego ^d   Mirshahi, Faridodin ^e   Sanyal, Arun J ^e   Sookoian, Silvia ^a,b  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b Hospital General de Agudos Dr Abel Zubizarreta   (Argentina)

^c Hospital Diego Thompson   (Argentina)

^d UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^e VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ARGONAUTE 2 PROTEIN; MICRORNA; MICRORNA 122; MICRORNA 125B; MICRORNA 192; MICRORNA 19A; MICRORNA 19B; MICRORNA 375; SMALL UNTRANSLATED RNA; UNCLASSIFIED DRUG; UNTRANSLATED RNA; AMINOTRANSFERASE; ARGONAUTE PROTEIN; BIOLOGICAL MARKER; EIF2C2 PROTEIN, HUMAN; MIRN122 MICRORNA, HUMAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; GENE; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER HISTOLOGY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MOLECULAR PATHOLOGY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SLC7A1 GENE; ANTHROPOMETRY; BIOPSY; BLOOD; CASE CONTROL STUDY; CELL CULTURE; COMPUTER SIMULATION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PHYSIOLOGY; PROCEDURES; UPREGULATION;

ADULT; ANTHROPOMETRY; ARGONAUTE PROTEINS; BIOMARKERS; BIOPSY; CASE-CONTROL STUDIES; CELLS, CULTURED; COMPUTER SIMULATION; FEMALE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER; MALE; MICRORNAS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RNA, UNTRANSLATED; TRANSAMINASES; UP-REGULATION;

EID: 84928885523     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-306996     Document Type: Article

References (42)

1. Selbach M, Schwanhausser B, Thierfelder N, et al. Widespread changes in protein synthesis induced by microRNAs. Nature 2008;455:58-63.
2. Weiland M, Gao XH, Zhou L, et al. Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases. RNA Biol 2012;9:850-9.
3. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res 2012;110:483-95.
4. Redis RS, Calin S, Yang Y, et al. Cell-to-cell miRNA transfer: from body homeostasis to therapy. Pharmacol Ther 2012;136:169-74.
5. Pirola CJ, Gianotti TF, Castano GO, et al. Circulating MicroRNA-122 signature in nonalcoholic fatty liver disease and cardiovascular disease: a new endocrine system in metabolic syndrome. Hepatology 2013;57:2545-7.
6. Brunt EM, Kleiner DE, Wilson LA, et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011;53:810-20.
7. Sookoian S, Rosselli MS, Gemma C, et al. Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor gamma coactivator 1alpha promoter. Hepatology 2010;52:1992-2000.
8. Pirola CJ, Gianotti TF, Burgueno AL, et al. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut 2013;62:1356-63.
9. Lonardo A, Sookoian S, Chonchol M, et al. Cardiovascular and systemic risk in nonalcoholic fatty liver disease-atherosclerosis as a major player in the natural course of NAFLD. Curr Pharm Des 2013;19:5177-92.
10. Meister G, Landthaler M, Patkaniowska A, et al. Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell 2004;15:185-97.
11. Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 2011;108:5003-8.
12. Chang J, Nicolas E, Marks D, et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004;1:106-13.
13. Yang Z, Venardos K, Jones E, et al. Identification of a novel polymorphism in the 30UTR of the L-arginine transporter gene SLC7A1: contribution to hypertension and endothelial dysfunction. Circulation 2007;115:1269-74.
14. Yang Z, Kaye DM. Mechanistic insights into the link between a polymorphism of the 30UTR of the SLC7A1 gene and hypertension. Hum Mutat 2009;30:328-33.
15. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005;438:685-9.
16. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007;318:1931-4.
17. Tay Y, Zhang J, Thomson AM, et al. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 2008;455:1124-8.
18. Sookoian S, Gianotti TF, Rosselli MS, et al. Liver transcriptional profile of atherosclerosis-related genes in human nonalcoholic fatty liver disease. Atherosclerosis 2011;218:378-85.
19. Cusi K, Chang Z, Harrison S, et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 2014;60:167-74.
20. Cheung O, Puri P, Eicken C, et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 2008;48:1810-20.
21. Choi Y, Dienes HP, Krawczynski K. Kinetics of miR-122 expression in the liver during acute HCV infection. PLoS ONE 2013;8:e76501.
22. Coulouarn C, Factor VM, Andersen JB, et al. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009;28:3526-36.
23. Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A 2009;106:4402-7.
24. Caldwell S, Ikura Y, Dias D, et al. Hepatocellular ballooning in NASH. J Hepatol 2010;53:719-23.
25. Li J, Ghazwani M, Zhang Y, et al. miR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression. J Hepatol 2013;58:522-8.
26. Bala S, Petrasek J, Mundkur S, et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced and inflammatory liver diseases. Hepatology 2012;56:1946-57.
27. Zhang Y, Jia Y, Zheng R, et al. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem 2010;56:1830-8.
28. Henke JI, Goergen D, Zheng J, et al. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J 2008;27:3300-10.
29. Lu H, Buchan RJ, Cook SA. MicroRNA-223 regulates Glut4 expression and cardiomyocyte glucose metabolism. Cardiovasc Res 2010;86:410-20.
30. Birney E, Stamatoyannopoulos JA, Dutta A, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 2007;447:799-816.
31. Khorshid M, Hausser J, Zavolan M, et al. A biophysical miRNA-mRNA interaction model infers canonical and noncanonical targets. Nat Methods 2013;10:253-5.
32. Kato M, Zhang J, Wang M, et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A 2007;104:3432-7.
33. Poy MN, Hausser J, Trajkovski M, et al. miR-375 maintains normal pancreatic alpha- and beta-cell mass. Proc Natl Acad Sci U S A 2009;106:5813-18.
34. Chung AC, Huang XR, Meng X, et al. miR-192 mediates TGF-beta/Smad3-driven renal fibrosis. J Am Soc Nephrol 2010;21:1317-25.
35. Gantier MP, Stunden HJ, McCoy CE, et al. A miR-19 regulon that controls NF-kappaB signaling. Nucleic Acids Res 2012;40:8048-58.
36. Villeneuve LM, Kato M, Reddy MA, et al. Enhanced levels of microRNA-125b in vascular smooth muscle cells of diabetic db/db mice lead to increased inflammatory gene expression by targeting the histone methyltransferase Suv39h1. Diabetes 2010;59:2904-15.
37. Friedman RC, Farh KK, Burge CB, et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009;19:92-105.
38. Zampetaki A, Mayr M. MicroRNAs in vascular and metabolic disease. Circ Res 2012;110:508-22.
39. Elmen J, Lindow M, Silahtaroglu A, et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res 2008;36:1153-62.
40. Tsai WC, Hsu SD, Hsu CS, et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 2012;122:2884-97.
41. Beaumont J, Lopez B, Hermida N, et al. microRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-beta1 up-regulation. Clin Sci (Lond) 2014;126:497-506.
42. Min HK, Kapoor A, Fuchs M, et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab 2012;15:665-74.